FDA rejects Aricept skin patch for Alzheimer's disease

04/25/2011 | Pharmaceutical Business Review Online · MedCityNews.com

The FDA declined to approve Eisai and Teikoku Pharma's weekly transdermal-patch version of Aricept, a treatment for Alzheimer's disease. The companies will review the agency's complete-response letter to determine their next step, Eisai said.

View Full Article in:

Pharmaceutical Business Review Online · MedCityNews.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT